Compare Motilal Oswal with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MOTILAL OSWAL vs INDOCO REMEDIES - Comparison Results

MOTILAL OSWAL     Change

Motilal Oswal Financial Services (MOFSL) derives a significant portion of its revenues from equity broking (69% in FY12) for both retail and institutional clients. Accordingly, its revenues and profits are dependent on favourable capital market condi... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MOTILAL OSWAL INDOCO REMEDIES MOTILAL OSWAL/
INDOCO REMEDIES
 
P/E (TTM) x 29.2 117.1 24.9% View Chart
P/BV x 4.1 2.0 208.3% View Chart
Dividend Yield % 0.7 0.7 101.3%  

Financials

 MOTILAL OSWAL   INDOCO REMEDIES
EQUITY SHARE DATA
    MOTILAL OSWAL
Mar-18
INDOCO REMEDIES
Mar-18
MOTILAL OSWAL/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,585317 499.4%   
Low Rs734178 412.2%   
Sales per share (Unadj.) Rs189.4113.1 167.5%  
Earnings per share (Unadj.) Rs38.74.5 866.5%  
Cash flow per share (Unadj.) Rs41.311.8 349.5%  
Dividends per share (Unadj.) Rs4.501.00 450.0%  
Dividend yield (eoy) %0.40.4 96.1%  
Book value per share (Unadj.) Rs156.473.2 213.5%  
Shares outstanding (eoy) m145.0892.15 157.4%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x6.12.2 279.4%   
Avg P/E ratio x30.055.5 54.0%  
P/CF ratio (eoy) x28.121.0 133.9%  
Price / Book Value ratio x7.43.4 219.2%  
Dividend payout %11.622.4 51.9%   
Avg Mkt Cap Rs m168,22822,830 736.9%   
No. of employees `000NA5.5 0.3%   
Total wages/salary Rs m5,0012,209 226.4%   
Avg. sales/employee Rs Th1,717,468.81,910.1 89,916.8%   
Avg. wages/employee Rs Th312,581.3405.0 77,186.7%   
Avg. net profit/employee Rs Th350,962.575.5 465,136.2%   
INCOME DATA
Net Sales Rs m27,48010,419 263.7%  
Other income Rs m21747 463.3%   
Total revenues Rs m27,69710,466 264.6%   
Gross profit Rs m12,7791,349 947.1%  
Depreciation Rs m375677 55.4%   
Interest Rs m4,956235 2,108.0%   
Profit before tax Rs m7,666484 1,583.9%   
Minority Interest Rs m-980-   
Prior Period Items Rs m910-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,04372 2,822.2%   
Profit after tax Rs m5,615412 1,364.3%  
Gross profit margin %46.512.9 359.1%  
Effective tax rate %26.715.0 178.2%   
Net profit margin %20.44.0 517.3%  
BALANCE SHEET DATA
Current assets Rs m29,0195,373 540.1%   
Current liabilities Rs m41,8354,157 1,006.4%   
Net working cap to sales %-46.611.7 -399.6%  
Current ratio x0.71.3 53.7%  
Inventory Days Days068 0.1%  
Debtors Days Days13973 190.4%  
Net fixed assets Rs m3,1136,244 49.9%   
Share capital Rs m145184 78.7%   
"Free" reserves Rs m22,5406,566 343.3%   
Net worth Rs m22,6856,750 336.1%   
Long term debt Rs m32,3291,233 2,622.4%   
Total assets Rs m98,64512,363 797.9%  
Interest coverage x2.53.1 83.3%   
Debt to equity ratio x1.40.2 780.3%  
Sales to assets ratio x0.30.8 33.1%   
Return on assets %10.75.2 204.9%  
Return on equity %24.86.1 405.9%  
Return on capital %22.99.0 254.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m03,762 0.0%   
Fx outflow Rs m01,143 0.0%   
Net fx Rs m02,619 0.0%   
CASH FLOW
From Operations Rs m1,1181,227 91.1%  
From Investments Rs m-1,907-1,360 140.2%  
From Financial Activity Rs m715-388 -184.5%  
Net Cashflow Rs m-91-521 17.4%  

Share Holding

Indian Promoters % 74.1 59.2 125.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 12.5 60.0%  
FIIs % 5.3 6.0 88.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.1 22.4 58.5%  
Shareholders   11,283 12,805 88.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MOTILAL OSWAL With:   RELIGARE ENT.  INGERSOLL RAND  FINOLEX INDUSTRIES  INDIABULLS FIN. SER.  COMPACT DISC  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

MOTILAL OSWAL Announces Quarterly Results (4QFY19); Net Profit Up 0.3% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MOTILAL OSWAL has posted a net profit of Rs 1 bn (up 0.3% YoY). Sales on the other hand came in at Rs 7 bn (down 12.7% YoY). Read on for a complete analysis of MOTILAL OSWAL's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MOTILAL OSWAL SHARE PRICE


Oct 17, 2019 (Close)

TRACK MOTILAL OSWAL

  • Track your investment in MOTILAL OSWAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MOTILAL OSWAL - TATA INVESTMENT COMPARISON

COMPARE MOTILAL OSWAL WITH

MARKET STATS